{
    "clinical_study": {
        "@rank": "105707", 
        "arm_group": {
            "arm_group_label": "Tarceva Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, multi-center study will evaluate the progression-free survival and safety\n      of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung\n      cancer with activating mutations in the tyrosine kinase domain of the epidermal growth\n      factor receptor (EGFR). Patients will receive daily oral doses of Tarceva until disease\n      progression or unacceptable toxicity."
        }, 
        "brief_title": "An Open-Label Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Diagnosis of locally advanced or metastatic non-small cell lung cancer with\n             activating mutations in the tyrosine kinase domain of the epidermal growth factor\n             receptor (EGFR)\n\n          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  Life expectancy >/=12 weeks\n\n          -  Adequate hematological, liver and renal function\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy or treatment against EGFR for metastatic disease\n\n          -  Treatment with an investigational agent less than 3 weeks before enrolment\n\n          -  History of neoplasm other than non-small cell lung cancer (except carcinoma in situ\n             of the uterine cervix, basal cell skin carcinoma, or prostate carcinoma)\n\n          -  Patients with symptomatic cerebral metastases\n\n          -  Any significant ophthalmologic abnormality\n\n          -  Unstable systemic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667562", 
            "org_study_id": "ML27860"
        }, 
        "intervention": {
            "arm_group_label": "Tarceva Arm", 
            "description": "Daily oral doses of 150 mg administered until disease progression or unacceptable toxicity", 
            "intervention_name": "erlotinib [Tarceva]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11080"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knez Selo", 
                        "country": "Serbia", 
                        "zip": "18000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sremska Kamenica", 
                        "country": "Serbia", 
                        "zip": "21204"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Serbia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IIIb, Open-label Study of Erlotinib (Tarceva\u00ae) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Serbia: Agency for Medicines and Medical Devices"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "Approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667562"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Safety: incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Incidence of epidermal growth factor receptor mutations in patients", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}